Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3Z5UQ)

• Drug Name: Benzo[d]oxazol-2(3H)-one derivative 3 Drug Info
• Synonyms: PMID29334795-Compound-65
• Cross-matching ID:
  PubChem CID: 118064262
  TTD Drug ID: DM3Z5UQ

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine H3 receptor (H3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pitolisant	DM8RFNJ	Excessive daytime sleepiness	MG42	Approved	[2]
SUVN-G3031	DM3BO8G	Cognitive impairment	6D71	Phase 3	[3]
JNJ-17216498	DM1GRCU	Narcolepsy	7A20	Phase 2	[4]
GSK239512	DMBJMZC	Alzheimer disease	8A20	Phase 2	[5]
JNJ-39220675	DM0WY3H	Alcohol dependence	6C40.2	Phase 2	[6]
AZD-5213	DMOZ04X	Alzheimer disease	8A20	Phase 2	[7]
Bavisant	DM6CVZ5	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[8]
ABT-288	DM7X54F	Alzheimer disease	8A20	Phase 2	[9]
SAR-110894	DMCLEXM	Alzheimer disease	8A20	Phase 2	[7]
ABT-652	DMLEO2Z	Diabetic neuropathy	8C0Z	Phase 2	[10]

Drug(s) Targeting Dopamine D2 receptor (D2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[11]
Haloperidol	DM96SE0	Delirium		Approved	[12]
Perphenazine	DMA4MRX	Schizophrenia	6A20	Approved	[13]
Perazine	DM2AOTZ	Psychotic disorder	6A20-6A25	Approved	[14]
Domperidone	DMBDPY0	Gastrointestinal disease	DE2Z	Approved	[15]
Levodopa	DMN3E57	Parkinson disease	8A00.0	Approved	[16]
Quetiapine	DM1N62C	Anorexia nervosa cachexia	6B80	Approved	[17]
Pimozide	DMW83TP	Schizophrenia	6A20	Approved	[18]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[19]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dopamine D2 receptor (D2R)	TTEX248	DRD2_HUMAN	Ligand	[1]
Histamine H3 receptor (H3R)	TT9JNIC	HRH3_HUMAN	Inhibitor	[1]

References

• [1] Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol. 2004 Nov;143(5):649-61.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41.
• [7] SAR110894, a potent histamine H receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav. 2012 Aug;102(2):203-14.
• [8] Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs. 2012 May 1;26(5):421-34.
• [9] A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia.J Alzheimers Dis.2014;42(3):959-71.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032225)
• [11] The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
• [12] Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperidol treatment. Synapse. 2002 Aug;45(2):78-85.
• [13] CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007 Nov;17(11):989-93.
• [14] Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg Med Chem. 2005 Jan 3;13(1):77-87.
• [15] Screening of domperidone in wastewater by high performance liquid chromatography and solid phase extraction methods. Talanta. 2006 Jan 15;68(3):928-31.
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3639).
• [17] Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40.
• [18] [The benzamides tiapride, sulpiride, and amisulpride in treatment for Tourette's syndrome]. Nervenarzt. 2007 Mar;78(3):264, 266-8, 270-1.
• [19] Modulatory role of dopamine D2 receptors and fundamental role of L-type Ca2+ channels in the induction of long-term potentiation in the basolateral... Eur J Pharmacol. 2009 Mar 15;606(1-3):90-3.
• [20] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.